Creative Planning Has $2.59 Million Stock Position in Merit Medical Systems, Inc. $MMSI

Creative Planning lowered its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 12.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,657 shares of the medical instruments supplier’s stock after selling 3,770 shares during the quarter. Creative Planning’s holdings in Merit Medical Systems were worth $2,585,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Evergreen Capital Management LLC lifted its position in Merit Medical Systems by 2.4% in the 1st quarter. Evergreen Capital Management LLC now owns 4,616 shares of the medical instruments supplier’s stock valued at $488,000 after acquiring an additional 108 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Merit Medical Systems by 55.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 134 shares in the last quarter. US Bancorp DE lifted its stake in Merit Medical Systems by 3.8% in the 1st quarter. US Bancorp DE now owns 3,936 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 145 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its stake in shares of Merit Medical Systems by 7.2% during the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 2,225 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 149 shares during the period. Finally, SageView Advisory Group LLC raised its position in shares of Merit Medical Systems by 3.1% in the first quarter. SageView Advisory Group LLC now owns 5,065 shares of the medical instruments supplier’s stock valued at $535,000 after purchasing an additional 153 shares during the period. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Price Performance

Shares of NASDAQ MMSI opened at $87.17 on Tuesday. The stock’s 50 day moving average price is $83.89 and its 200-day moving average price is $88.43. The company has a market capitalization of $5.17 billion, a PE ratio of 44.25, a PEG ratio of 2.62 and a beta of 0.64. Merit Medical Systems, Inc. has a twelve month low of $78.12 and a twelve month high of $111.45. The company has a quick ratio of 2.66, a current ratio of 4.09 and a debt-to-equity ratio of 0.49.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.10. The company had revenue of $384.16 million for the quarter, compared to analysts’ expectations of $371.69 million. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. Merit Medical Systems’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 EPS. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. On average, equities analysts anticipate that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, Chairman Fred P. Lampropoulos sold 25,000 shares of Merit Medical Systems stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $87.31, for a total transaction of $2,182,750.00. Following the completion of the sale, the chairman directly owned 1,029,955 shares in the company, valued at $89,925,371.05. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 50,000 shares of company stock valued at $4,309,500. Company insiders own 3.20% of the company’s stock.

Analyst Upgrades and Downgrades

MMSI has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, November 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a report on Monday, November 17th. Canaccord Genuity Group decreased their price target on shares of Merit Medical Systems from $104.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Needham & Company LLC restated a “buy” rating and set a $108.00 price objective on shares of Merit Medical Systems in a research report on Friday, October 31st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $109.00 price target (up previously from $105.00) on shares of Merit Medical Systems in a research report on Friday, October 31st. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.50.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.